Physician profile
Janet Galanes
NPI 1235178856
$16,497.39
in general payments reported to CMS, 2019-2025
53 companies · $4,347 in 2025
The $4,347 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,921 · 2020: $262 · 2021: $779 · 2022: $1,872 · 2023: $3,335 · 2024: $3,981 · 2025: $4,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $63.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,599.11 |
| Education | $63.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,737.98 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,602.54 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,357.44 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,239.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,210.90 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $1,202.44 | 2019-2025 | |
| Glaxosmithkline, LLC. | $790.07 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $615.37 | 2022-2025 | Auvelity, Sunosi |
| Bayer Healthcare Pharmaceuticals INC. | $590.64 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $472.89 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.73 | 2019-2025 | Jardiance |
| Vanda Pharmaceuticals INC. | $388.94 | 2025 | Fanapt |
| Lundbeck LLC | $387.25 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $382.05 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $366.45 | 2022-2025 | Caplyta |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $304.81 | 2019-2024 | Yupelri |
| Corium, LLC | $280.53 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $267.49 | 2019-2025 | Trintellix |
| Sumitomo Pharma America, INC. | $237.67 | 2023-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $228.98 | 2023-2025 | Rexulti |
| Radius Health, INC. | $224.40 | 2019-2025 | Tymlos |
| Abbott Laboratories | $221.58 | 2021-2025 | Freestyle Libre 3, Eterna |
| Astellas Pharma US INC | $221.42 | 2019-2024 | Veozah, Myrbetriq |
| Ardelyx, INC. | $211.90 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $200.22 | 2019-2023 | Belsomra |
| Exact Sciences Corporation | $172.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $146.98 | 2019-2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $79.01 | 2022 | |
| Idorsia Pharmaceuticals US INC | $76.09 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $70.21 | 2021-2025 | Nexletol |
| Biogen, INC. | $68.70 | 2021-2025 | Zurzuvae |
| Eisai INC. | $68.09 | 2019-2022 | |
| Ibsa Pharma INC. | $64.25 | 2023-2025 | Tirosint, Tirosint, Licart |
| Supernus Pharmaceuticals, INC. | $57.44 | 2021-2024 | Qelbree, Qelbree |
| Biohaven Pharmaceutical Holding Company LTD. | $56.37 | 2022 | |
| Dexcom, INC. | $53.25 | 2023-2025 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $46.76 | 2019 | |
| Viatris Specialty LLC | $43.57 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $40.26 | 2024 | Inspire |
| Ironwood Pharmaceuticals, INC | $35.30 | 2024 | |
| Neurocrine Biosciences, INC. | $34.67 | 2025 | |
| Jazz Pharmaceuticals INC. | $31.54 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $26.72 | 2021-2023 | Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.03 | 2019 | |
| Horizon Therapeutics Plc | $23.69 | 2021 | |
| Shield Therapeutics INC | $22.04 | 2024 | |
| Collegium Pharmaceutical, INC. | $20.96 | 2025 | Jornay Pm |
| Phathom Pharmaceuticals, INC. | $16.90 | 2024 | Voquezna |
| Sanofi Pasteur INC. | $15.52 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.04 | 2021 | |
| Genentech USA, INC. | $13.96 | 2022 | |
| Rhodes Pharmaceuticals L.P. | $13.95 | 2019 | |
| Allergan, INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Galanes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.